LE ROUX, JACQUES,LERICHE, CAROLINE,AUCLAIR, ERIC,MIDDLEMISS, DAVID, N
申请号：
NZ59394909
公开号：
NZ593949A
申请日:
2009.12.18
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
593949 Disclosed are compounds of formula (I) where the substituents are as disclosed in the specification. Examples of compounds of formula (I) include: [(R)-1-(2-{ 4-[6-(2-Chloro-5-hydroxy-phenyl)-quinazolin-2-ylamino]-phenoxy} -acetyl)-pyrrolidin-3-yl]-dimethyl-ammonium； 4-Chloro-3-[2-(3-hydroxymethyl-phenylamino)-8-methyl-quinazolin-6-yl]-phenol； (R)-1-(2-{ 4-[6-(2-Chloro-5-hydroxy-phenyl)-8-methyl-quinazolin-2-ylamino]-phenoxy} -ethyl)-pyrrolidine-2-carboxylic acid. The compounds are useful in the treatment of a disorder involving tyrosine kinase dysregulation or an ophthalmic disorder such as myocardial infarction, stroke, congestive heart failure, an ischemia or reperfusion injury, trauma, cancer, oedema, arthritis or other arthropathy, retinopathy or vitreoretinal disease, diabetic retinopathy, macular oedema, including diabetic macular oedema, macular degeneration, glaucoma, autoimmune disease, vascular leakage syndrome, inflammatory disease, oedema, transplant rejection, burn, or acute or adult respiratory distress syndrome.
